Principal Medical has developed the AngioShield infusion filter, a small-caliber tethered filter that provides safe and easy PE prophylaxis. The AngioShield can be inserted through existing single lumen central lines to guard against emboli. If needed, tPA can be infused through the lumen of the catheter to dissolve clot. Deployment and retrieval of the catheter are extremely simple and can be done at bedside without additional procedures.
Over 5 million people annually in the US go to the ICU. Nearly all ICU patients are at risk for DVT and PE [1] and require thromboprophylaxis.
A significant proportion of ICU patients are contraindicated for chemical thromboprophylaxis. At least 15% of ICU patients are contraindicated [2]. This includes patients from the surgical ICU.
The AngioShield provides simple PE prophylaxis with a maximum of one additional procedure, and no additional procedures for patients with an existing single lumen CVC that the AngioShield can be placed in.
[1] Williams, M. T., Aravindan, N., Wallace, M. J., Riedel, B. J. C. J., & Shaw, A. D. (2003). Venous thromboembolism in the intensive care unit. Review Crit Care Clin, 19(2), 185-207. doi: 10.1016/s0749-0704(02)00048-9.
[2] Fowler, A. L., Cullivan, O., Sibartie, S., O’Shea, A., Waldron, R., Khan, I., Khan, W., & Barry, K. M. (2019). Utilisation of critical care services for surgical patients in a model three hospital. Irish Journal of Medical Science (1971 -), 188, 1137-1142. doi: 10.1007/s11845-018-1917-6.
Plan
- This is a sell sheet for the infusion filter
Required elements:
- Image
- Video
- Problem background
- Solution
- Main selling points
- Physician selling points
- Investor selling points
Additionally
- Cite studies
Background
In the past decade, hospitalizations from clots have increased 30% and deaths have increased 50%.
Over 100,000 people die from DVT each year. It costs $20k per treatment and over $10B per year to the US. Our aging population is at risk for DVT and, subsequently, PE.
Currently, DVT is treated with one of:
Problem
Existing methods of thrombectomy have problems
- Do not clear leg fully
- Large entry hole, possible venous injury
- Large caliber catheter scraping endothelium, possible trauma
- Backwards movement traumatic to deep vein valves
- Can require notorious IVC filter
Existing methods of filtration during thrombolysis and thrombectomy have problems
- Filters often cannot be retrieved, leading to health issues for patients and lawsuits for companies/physicians
- Currently, no temporary filters work alongside existing thrombectomy/thrombolysis catheters
Solution
Principal Medical has developed a small caliber tPA infusion wire which, upon deployment, curls into a tethered IVC filter. Upon removal, the IVC is curled into a straight wire shape.
This results in a significantly safer and more effective DVT treatment than any currently existing treatment.